Table 2.

Abbreviated summary recommendations for screening and prevention of late complications in long-term HCT survivors organized by time after transplantation

Recommended Screening/Prevention	6 mo	1yr	Annually
Immunity
Encapsulated organism prophylaxis	2	2	2
PCP prophylaxis	2	2
CMV testing	2	2	2
Immunizations	1	1	1
Ocular
Ocular clinical symptom evaluation	1	1	1
Ocular fundus exam	+	1	+
Oral Complications
Clinical assessment	1	1	1
Dental assessment	+	1	1
Respiratory
Clinical pulmonary assessment	1	1	1
Smoking tobacco avoidance	1	1	1
Pulmonary function testing	+	+	+
Chest radiography	+	+	+
Cardiac and vascular
Cardiovascular risk-factor assessment	+	1	1
Liver
Liver function testing	1	1	+
Serum ferritin testing		1	+
Kidney
Blood pressure screening	1	1	1
Urine protein screening	1	1	1
BUN/creatinine testing	1	1	1
Muscle and connective tissue
Evaluation for muscle weakness	2	2	2
Physical activity counseling	1	1	1
Skeletal
Bone density testing (adult women, all allogeneic transplant recipients and patients at high risk for bone loss)		1	+
Nervous system
Neurologic clinical evaluation	+	1	1
Evaluate for cognitive development		1	1
Endocrine
Thyroid function testing		1	1
Growth velocity in children		1	1
Gonadal function assessment (prepubertal men and women)	1	1	1
Gonadal function assessment (postpubertal women)		1	+
Gonadal function assessment (postpubertal men)		+	+
Muco-cutaneous
Skin self-exam and sun exposure counseling	1	1	1
Gynecologic exam in women	+	1	1
Second cancers
Second cancer vigilance counseling		1	1
Screening for second cancers		1	1
Psychosocial
Psychosocial/QOL clinical assessment	1	1	1
Sexual function assessment	1	1	1

1 = recommended for all transplant recipients

2 = recommended for any patient with ongoing chronic GVHD or immunosuppression

+ = reassessment recommended for abnormal testing in a previous time period or for new signs/symptoms